Amgen Inc. (AMGN) Completes Phase 3 Trial for ABP 206 Opdivo Biosimilar Candidate

Group 1 - Amgen Inc. is recognized as one of the top 10 stocks to invest in during a recession [1] - The Phase 3 study for ABP 206, a biosimilar candidate for Opdivo, has been completed, enrolling 256 subjects with advanced melanoma [2] - Wells Fargo has raised Amgen's price target from $325 to $375 while maintaining an Equal Weight rating, reflecting updates in its valuation model [3] Group 2 - Amgen, founded in 1980, is a leading global biotechnology company focused on innovative human therapeutics for serious illnesses [4] - The successful outcome of the ABP 206 trial could position Amgen as a key provider of lower-cost immunotherapy for advanced melanoma [2]